ACTC Announces Completion of Higher Dosage

ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials Three Patients with Forms of Macular Degeneration Injected with 100,000 hESC-Derived RPE Cells, Successfully Completing Second Cohort...................................... ......................................................................................................................................................................................................................................................................Great news for ACTC closed at 0.0622. Need results and a partner with lots of money. . ......................................................................................................................................................................................................................................................................Geron closed up 4 cent at $1.42 on light volume. I would think we should run up more before results of Phase 2 trials............................................... ............................................................................................................................................................................. BTX closed up 6 cents on light volume. It's hard to believe this company will get Geron's stem cell property for pennies on the dollar. Soon I will be adding BioTime as the future of bio tech.............................................................. Good luck in this rigged casino,